In the pharmaceutical industry, Montelukast (Singulair) is a leukotriene receptor antagonist. As a pharmacist and manufacturer, I view its dosing schedule through the lens of Circadian Pharmacotherapy: the “best” time to take it is not a matter of convenience, but is technically dictated by the specific condition being treated to align with the body’s natural inflammatory peaks.

At your WHO-GMP facility in Mumbai, where you likely manufacture the 4 mg, 5 mg, and 10 mg tablets (including dispersible and granule forms), providing these specific timing protocols is a vital technical value-add for your B2B respiratory and allergy portfolio.

Therapeutic Profile: Dosing by Indication

The technical recommendation for “Day vs. Night” varies based on the pathology:

Indication	Recommended Timing	Technical Rationale
Asthma	Evening / Night	Asthma symptoms (wheezing, coughing) and leukotriene levels naturally peak in the early morning hours (circadian rhythm). Evening dosing ensures peak plasma levels ($T_{max}$ in 3-4 hours) occur when the patient is most vulnerable.
Allergic Rhinitis	Flexible (Same time daily)	For seasonal or year-round allergies, efficacy is similar whether taken in the morning or evening. The goal is a steady state in the blood.
Exercise-Induced	2 Hours Before Exercise	A single dose provides protection for up to 24 hours. Taking it 2 hours prior ensures the drug has reached therapeutic concentrations before the lungs are stressed.
Both Asthma + Allergies	Evening / Night	If treating both, the asthma protocol (Evening) takes priority.

Mechanism: Cysteinyl Leukotriene Receptor Blockade

Montelukast works by physically “plugging” the receptors that would otherwise cause inflammation:

Chemical Signal: The body releases leukotrienes (inflammatory chemicals) in response to triggers like pollen or cold air.

Receptor Binding: These leukotrienes bind to CysLT1 receptors on the smooth muscle cells of the lungs and nasal lining.

Reaction: This binding causes the airways to swell (edema), constrict (bronchospasm), and produce excess mucus.

The Blockade: Montelukast sits on these receptors, preventing the leukotrienes from binding. This keeps the airways open and the nasal passages clear.

The Pharmacist’s “Technical Warning”

• The “Boxed Warning” (2026 Alert): As a pharmacist, I must emphasize the FDA/global warning regarding Neuropsychiatric Events. Monitor patients for changes in mood, aggression, or suicidal thoughts.

• The “Nightmare” Connection: While taking it at night is best for asthma, some patients experience vivid dreams or insomnia. If these sleep disturbances occur, a doctor may suggest a trial of morning dosing for asthma, even if it is technically “off-label” from the standard protocol.

• Not a Rescue Inhaler: Montelukast is for prevention, not for treating an acute asthma attack. Patients must always carry a short-acting beta-agonist (like Albuterol).

• Consistency is Key: The therapeutic effect occurs within one day, but maximum control is only achieved with consistent daily dosing.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

• The “Granule Formulation” USP: On your digital marketplace, highlight your 4 mg Oral Granules. These are a high-demand SKU for pediatric patients (ages 12-23 months) who cannot swallow tablets. They can be mixed with soft foods (applesauce/yogurt) but must be consumed within 15 minutes.

• Stability for Export: Montelukast is sensitive to light and moisture. Utilizing Alu-Alu blister packaging is the industry standard for ensuring a 36-month shelf life in Zone IVb tropical regions.

• Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers to support your firm’s registration in international tenders for respiratory and pediatric health.